ANIP - NASDAQ
ANI Pharmaceuticals, Inc.
$75.23
-1.9%ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
At a Glance
Live SnapshotANI Pharmaceuticals, Inc. Management Team
Ms. Elizabeth Powell J.D.
Chief Compliance Officer & Head of Legal of Rare Disease
Dr. Mary Pao M.D., Ph.D.
Chief Medical Officer
Mr. Muthusamy Shanmugam MS R.Ph.
Head of R&D, Chief Operating Officer of New Jersey Operations & Director
Mr. Nikhil Lalwani
President, Chief Executive Officer & Director
Compensation
$2,439,171
Ms. Krista L. Davis
Senior Vice President & Chief Human Resources Officer
Mr. Christopher K. Mutz
Senior Vice President & Head of Rare Disease
Compensation
$919,663
Mr. Chad Gassert
Senior Vice President of Corporate Development & Strategy
Compensation
$849,711
Mr. Stephen P. Carey
Senior Vice President of Finance & Chief Financial Officer
Compensation
$1,138,453
Mr. Ori Gutwerg
Senior Vice President of Generics
Compensation
$930,962
Ms. Meredith W. Cook J.D.
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$845,500
ANI Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $22.96M worth of ANIP shares, with no buying activity reported.
3 Months
0
0.00
93.9K
7.26M
-7.3M
-$7.26M
3-6 Months
0
0.00
31.0K
2.38M
-2.4M
-$2.38M
6-9 Months
0
0.00
29.1K
2.58M
-2.6M
-$2.58M
9-12 Months
0
0.00
118.4K
10.73M
-10.7M
-$10.73M
Top Buyers
No buying activity
Top Sellers
Shanmugam Muthusamy
Director, Officer: Head Of R&D, Coo-Novitium Ops
$9.04M
Lalwani Nikhil
Director, Officer: President & Ceo
$4.27M
Walsh Patrick D
Director
$2.32M
Mutz Christopher
Officer: Head Of Rare Disease
$1.64M
Davis Krista
Officer: Svp, Chief Hr Officer
$1.34M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $22.96M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
ANIP - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 09, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 10, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 05, 2024 | December 31, 2023 | 2023 | |
DEF 14A DEF 14A N/A | April 11, 2023 | April 11, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 25, 2022 | April 27, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 02, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | June 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 04, 2019 | May 14, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 06, 2018 | May 17, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 06, 2017 | May 17, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.